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This article discusses the potential of levosimendan
to treat calcium-induced myocardial dysfunction
associated with deep hypothermia. Moderate
hypothermia (30 to 34°C) usually improves myocardial
contractility and stabilizes heart rhythm, but deep
hypothermia can cause severe myocardial dysfunction,
which is mediated by intracellular calcium overload. In
experimental studies, levosimendan appears effective
in reversing this. Clinical studies are needed to confirm
these findings and to determine whether levosimendan
could also be used for accidental hypothermia and
perhaps to mitigate diastolic dysfunction under moderate
hypothermia.stolic relaxation, in turn, is rate-limited by removal of
2+Lowering core temperature has complex and divergent
effects on the myocardium, stimulating or inhibiting
contractility and heart rhythm through several different
mechanisms. The effects vary with the depth of
hypothermia and are influenced by volume status, heart
rate (which itself is affected by hypothermia), endocrine
factors, and (crucially) extracellular and intracellular
electrolyte concentrations. In general, moderate
hypothermia (30 to 34°C) improves myocardial contract-
ility whereas deep hypothermia (<28°C) has the opposite
effect. Under specific circumstances (presence of tachy-
cardia, hypovolemia, or electrolyte disorders), moderate
hypothermia can also cause myocardial dysfunction.
Electrolytes, particularly calcium, play a key role in
maintaining myocardial contractility through mecha-
nisms that are also temperature-dependent. In the previ-
ous issue of Critical Care, Rungatscher and colleaguesCorrespondence: k.polderman@tip.nl
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© BioMed Central Ltd.2013[1] present the results of a study on a key issue affecting
deep hypothermic circulatory arrest (DHCA): reversing
calcium-mediated persistent myocardial dysfunction
after rewarming from DHCA.
Moderate hypothermia (30 to 34°C) increases intracel-
lular Ca2+ transients in a dose-dependent fashion,
thereby increasing myocardial contractility [2]. However,
deep hypothermia (<28°C) can lead to intracellular cal-
cium overload, especially when hypothermia is main-
tained for more than 30 minutes [3-5]. Intracellular
hypercalcemia is corrected only slowly during and after
rewarming from deep hypothermia, often leading to per-
sistent myocardial dysfunction [3-5]. In addition, deep
hypothermia can induce calcium desensitization, which
usually develops during rewarming after DHCA. Dia-
Ca from the cytoplasm and the rate of cross-bridge de-
tachment [6].
These issues are further complicated by hypothermia-
induced changes in excretion of calcium and other elec-
trolyte levels as well as on electrolyte shifts and changes
in intracellular pH. Urinary electrolyte excretion can in-
crease markedly during induction of hypothermia, and a
pronounced intracellular shift of potassium, magnesium,
phosphate, calcium, and (to a lesser extent) sodium will
occur [7-9]. This intracellular shift is reversed when the
patient is rewarmed [7,8]. All this can have profound ef-
fects on the myocardium; this applies in particular to
hypocalcemia, which can cause myocardial dysfunction,
hypotension, arrhythmias, and failure to respond to
drugs that act through calcium-mediated mechanisms
(norepinephrine, dopamine, digoxin, and so on). Defi-
ciencies of magnesium, potassium, and phosphate can
also induce myocardial dysfunction and arrhythmias [7].
Conversely, intracellular influx of magnesium can help
stabilize cellular membranes, improve intracellular
Polderman Critical Care Page 2 of 32013, 17:1018
http://ccforum.com/content/17/6/1018energy management, and mitigate effects of calcium
overload (which can occur during deep hypothermia but
also during ischemia) [7,8]. In addition, intracellular pH
increases during hypothermia, potentially enhancing
myocardial contractility by offsetting the calcium-
desensitizing effect of hypothermia [10,11]. Intracellular
Na+ can also increase, leading to increased production
of reactive oxygen species (ROS) in the mitochondria
[12]. This may initially improve intracellular homeostasis
through more effective intracellular signaling and energy
management [13], but when the rise is excessive, ROS
can severely damage intracellular structures [7,13]. How-
ever, in yet another twist, mild hypothermia itself miti-
gates excessive ROS production, countering the
potentially dangerous nitric oxide synthase toxicity [7].
Thus, the effects of moderate hypothermia on electro-
lytes in general and on calcium in particular are convo-
luted, with numerous and often conflicting effects on
myocardial tissue. However, with deep hypothermia,
some myocardial dysfunction will almost invariably
occur, which is mediated to a substantial degree by intra-
cellular calcium overload.
Epinephrin is the drug most commonly used to treat
refractory hypotension in this situation. Rungatscher and
colleagues [1] compared epinephrine with the calcium
sensitizer levosimendan to reverse myocardial dysfunc-
tion after rewarming from DHCA in a rat model. They
report that levosimendan was significantly more effective
in reversing systolic and diastolic myocardial dysfunc-
tion, independent of volume status. Levosimendan also
improved ventricular relaxation, better preserved myo-
cardial ATP content, and reduced plasma lactate con-
centrations [1].
The same authors previously reported that levosimen-
dan has better inotropic and lusitropic effects than epi-
nephrine during rewarming from DHCA [14]. Others
have published similar findings, with positive inotropic
effects of levosimendan irrespective of the temperature.
Given these experimental data, levosimendan appears
to be a highly promising drug to improve myocardial
function during and after deep hypothermia, with a
number of theoretical advantages over the commonly
used epinephrine. The drug now needs to be evaluated
in clinical studies, not just in DHCA but also for acci-
dental hypothermia, in which rewarming is often com-
plicated by major hemodynamic problems.
Given the mechanisms outlined above, hemodynamic
effects of hypothermia can be hard to predict. Moderate
hypothermia (30 to 34°C), induced under controlled
conditions (euvolemia, preventing discomfort through
sedation or other means, preserving normal serum elec-
trolyte levels), will usually decrease heart rate, reduce
risk of arrhythmias, markedly improve systolic function,
and induce mild diastolic dysfunction. Under optimalconditions, the diastolic dysfunction has only minimal
effects on myocardial performance, and the overall effect
of cooling will be an improvement in myocardial con-
tractility, increase in stroke volume, reduction in cardiac
output (CO) because of the decrease in heart rate, and
stabilization or slight increase in blood pressure [7]. In-
deed, several clinical studies have reported the successful
use of hypothermia to treat refractory cardiac shock [7].
The balance between metabolic supply and demand im-
proves because the decrease in metabolic demand (7% to
10% per °C decrease in core temperature) exceeds the
drop in CO [7].
However, under different conditions (especially the
presence of tachycardia), myocardial contractility may be
adversely affected even under moderate hypothermia [7].
Several studies have shown that increasing heart rate
under normothermic conditions improves myocardial
contractility and CO but that increasing heart rate under
hypothermic conditions decreases myocardial contractil-
ity [7,15]. There is also a dichotomy in temperature ef-
fect on heart rhythm: membrane stabilization and
decreased risk of arrhythmias with moderate
hypothermia, increased risk of arrhythmias with deep
hypothermia (<28°C) [7].
The results of the study by Rungatscher and colleagues
[1] for deep hypothermia suggest that levosimendan
could potentially also be used to reverse the mild dia-
stolic dysfunction that occurs in many patients during
moderate hypothermia. However, it is too early to rec-
ommend the use of this promising drug outside the con-
text of clinical trials.
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